189 related articles for article (PubMed ID: 9623011)
21. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
[TBL] [Abstract][Full Text] [Related]
22. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
23. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
24. Modification in sucrose tolerance test with acarbose, guargum and their combination in patients with non-insulin dependent diabetes.
Shah PK; Lakhotia M; Purohit A; Jain SK; Gupta SK; Bhandari P
J Assoc Physicians India; 1993 Nov; 41(11):703-5. PubMed ID: 8005921
[TBL] [Abstract][Full Text] [Related]
25. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
26. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB; Bray GA
Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
[TBL] [Abstract][Full Text] [Related]
27. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo.
Calle-Pascual A; Garcia-Honduvilla J; Martin-Alvarez PJ; Calle JR; Maranes JP
Diabetes Metab; 1996 Jun; 22(3):201-2. PubMed ID: 8697309
[No Abstract] [Full Text] [Related]
28. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
29. [Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure].
Heuer LJ; Kaufmann HH
Dtsch Z Verdau Stoffwechselkr; 1985; 45(2):52-8. PubMed ID: 3924553
[TBL] [Abstract][Full Text] [Related]
30. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus.
Li C; Hung YJ; Qamruddin K; Aziz MF; Stein H; Schmidt B
Diabetes Res Clin Pract; 2011 Apr; 92(1):57-64. PubMed ID: 21251726
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB
Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
[TBL] [Abstract][Full Text] [Related]
32. [Acarbose, an unduly neglected antidiabetic drug].
Iványi J; Gyimesi A
Orv Hetil; 1996 Dec; 137(49):2737-41. PubMed ID: 9679608
[TBL] [Abstract][Full Text] [Related]
33. Acarbose for diabetes mellitus.
Med Lett Drugs Ther; 1996 Feb; 38(967):9-10. PubMed ID: 8559114
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
Hoffmann J; Spengler M
Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
[TBL] [Abstract][Full Text] [Related]
36. Effects of beano on the tolerability and pharmacodynamics of acarbose.
Lettieri JT; Dain B
Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
[TBL] [Abstract][Full Text] [Related]
38. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
[TBL] [Abstract][Full Text] [Related]
39. Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus.
Agrawal P; Rai V; Singh RB
Int J Clin Pharmacol Ther; 1996 Sep; 34(9):406-9. PubMed ID: 8880292
[TBL] [Abstract][Full Text] [Related]
40. A review of the safety and efficacy of acarbose in diabetes mellitus.
Yee HS; Fong NT
Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
